Population
BALB/c mice infected with lactate dehydrogenase-elevating virus for 6 days and immunosuppressed 10-month-old…
Comparison
Monoclonal antibodies to LDV vs Polyclonal mouse anti-LDV IgG
Design
Preclinical
Authors
Loading...
VP-3 mAbs lack neutralizing or protective activity in LDV models; leaves open identification of alternative epitopes for vaccine research.
Monoclonal antibodies specific to the LDV VP-3 glycoprotein do not neutralize viral infectivity or provide in vivo protection against LDV-induced poliomyelitis.
Harty et al. (1987) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: